Long term follow-up of women treated for screen detected atypical ductal hyperplasia or lobular neoplasia in a large UK screening centre
Background Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention...
Saved in:
| Published in | BJC reports Vol. 2; no. 1; pp. 90 - 7 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
18.12.2024
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2731-9377 2731-9377 |
| DOI | 10.1038/s44276-024-00113-2 |
Cover
| Abstract | Background
Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies.
Methods
Women diagnosed with screen detected ADH and/or LN between 2010-2018 at our institution were identified and demographic data, MDT decisions and BC diagnoses extracted from electronic patient records in 2019 and 2023.
Results
Of 107 women, 74 were discharged to the NHS Breast Screening Programme and 33 were offered enhanced screening (ES). The proportion offered ES increased significantly over time (
p
= 0.037). 15/105 (14.3%) developed BC (median follow-up 117 months), 9 screen-detected and 6 symptomatic, with 3 interval cancers diagnosed 12–25 months following their last screen. 3/15 were lymph node positive and 13/14 invasive cancers were estrogen receptor (ER) positive. BC incidence rate was 1499.6/100,000 women/year (SIR = 4.7), lower in the first 5 years of follow-up compared with post 5 years.
Conclusions
In women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours. |
|---|---|
| AbstractList | Background
Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies.
Methods
Women diagnosed with screen detected ADH and/or LN between 2010-2018 at our institution were identified and demographic data, MDT decisions and BC diagnoses extracted from electronic patient records in 2019 and 2023.
Results
Of 107 women, 74 were discharged to the NHS Breast Screening Programme and 33 were offered enhanced screening (ES). The proportion offered ES increased significantly over time (
p
= 0.037). 15/105 (14.3%) developed BC (median follow-up 117 months), 9 screen-detected and 6 symptomatic, with 3 interval cancers diagnosed 12–25 months following their last screen. 3/15 were lymph node positive and 13/14 invasive cancers were estrogen receptor (ER) positive. BC incidence rate was 1499.6/100,000 women/year (SIR = 4.7), lower in the first 5 years of follow-up compared with post 5 years.
Conclusions
In women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours. Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies.BACKGROUNDAtypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies.Women diagnosed with screen detected ADH and/or LN between 2010-2018 at our institution were identified and demographic data, MDT decisions and BC diagnoses extracted from electronic patient records in 2019 and 2023.METHODSWomen diagnosed with screen detected ADH and/or LN between 2010-2018 at our institution were identified and demographic data, MDT decisions and BC diagnoses extracted from electronic patient records in 2019 and 2023.Of 107 women, 74 were discharged to the NHS Breast Screening Programme and 33 were offered enhanced screening (ES). The proportion offered ES increased significantly over time (p = 0.037). 15/105 (14.3%) developed BC (median follow-up 117 months), 9 screen-detected and 6 symptomatic, with 3 interval cancers diagnosed 12-25 months following their last screen. 3/15 were lymph node positive and 13/14 invasive cancers were estrogen receptor (ER) positive. BC incidence rate was 1499.6/100,000 women/year (SIR = 4.7), lower in the first 5 years of follow-up compared with post 5 years.RESULTSOf 107 women, 74 were discharged to the NHS Breast Screening Programme and 33 were offered enhanced screening (ES). The proportion offered ES increased significantly over time (p = 0.037). 15/105 (14.3%) developed BC (median follow-up 117 months), 9 screen-detected and 6 symptomatic, with 3 interval cancers diagnosed 12-25 months following their last screen. 3/15 were lymph node positive and 13/14 invasive cancers were estrogen receptor (ER) positive. BC incidence rate was 1499.6/100,000 women/year (SIR = 4.7), lower in the first 5 years of follow-up compared with post 5 years.In women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours.CONCLUSIONSIn women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours. Abstract Background Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies. Methods Women diagnosed with screen detected ADH and/or LN between 2010-2018 at our institution were identified and demographic data, MDT decisions and BC diagnoses extracted from electronic patient records in 2019 and 2023. Results Of 107 women, 74 were discharged to the NHS Breast Screening Programme and 33 were offered enhanced screening (ES). The proportion offered ES increased significantly over time (p = 0.037). 15/105 (14.3%) developed BC (median follow-up 117 months), 9 screen-detected and 6 symptomatic, with 3 interval cancers diagnosed 12–25 months following their last screen. 3/15 were lymph node positive and 13/14 invasive cancers were estrogen receptor (ER) positive. BC incidence rate was 1499.6/100,000 women/year (SIR = 4.7), lower in the first 5 years of follow-up compared with post 5 years. Conclusions In women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours. Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies. Women diagnosed with screen detected ADH and/or LN between 2010-2018 at our institution were identified and demographic data, MDT decisions and BC diagnoses extracted from electronic patient records in 2019 and 2023. Of 107 women, 74 were discharged to the NHS Breast Screening Programme and 33 were offered enhanced screening (ES). The proportion offered ES increased significantly over time (p = 0.037). 15/105 (14.3%) developed BC (median follow-up 117 months), 9 screen-detected and 6 symptomatic, with 3 interval cancers diagnosed 12-25 months following their last screen. 3/15 were lymph node positive and 13/14 invasive cancers were estrogen receptor (ER) positive. BC incidence rate was 1499.6/100,000 women/year (SIR = 4.7), lower in the first 5 years of follow-up compared with post 5 years. In women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours. BackgroundAtypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies.MethodsWomen diagnosed with screen detected ADH and/or LN between 2010-2018 at our institution were identified and demographic data, MDT decisions and BC diagnoses extracted from electronic patient records in 2019 and 2023.ResultsOf 107 women, 74 were discharged to the NHS Breast Screening Programme and 33 were offered enhanced screening (ES). The proportion offered ES increased significantly over time (p = 0.037). 15/105 (14.3%) developed BC (median follow-up 117 months), 9 screen-detected and 6 symptomatic, with 3 interval cancers diagnosed 12–25 months following their last screen. 3/15 were lymph node positive and 13/14 invasive cancers were estrogen receptor (ER) positive. BC incidence rate was 1499.6/100,000 women/year (SIR = 4.7), lower in the first 5 years of follow-up compared with post 5 years.ConclusionsIn women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours. |
| ArticleNumber | 90 |
| Author | Gandhi, Ashu Lim, Yit Brown, Nicole L. Harkness, Elaine F. Evans, Dafydd Gareth Pritchard, Susan Howell, Anthony Howell, Sacha J. |
| Author_xml | – sequence: 1 givenname: Nicole L. surname: Brown fullname: Brown, Nicole L. organization: Manchester University NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road – sequence: 2 givenname: Susan surname: Pritchard fullname: Pritchard, Susan organization: Manchester University NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road – sequence: 3 givenname: Elaine F. surname: Harkness fullname: Harkness, Elaine F. organization: Division of Informatics, Imaging and Data Sciences, The University of Manchester – sequence: 4 givenname: Yit surname: Lim fullname: Lim, Yit organization: Manchester University NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road – sequence: 5 givenname: Ashu surname: Gandhi fullname: Gandhi, Ashu organization: Manchester University NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road, Division of Cancer Sciences, The University of Manchester – sequence: 6 givenname: Dafydd Gareth surname: Evans fullname: Evans, Dafydd Gareth organization: Manchester University NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road, Division of Evolution, Infection and Genomic Sciences, The University of Manchester – sequence: 7 givenname: Anthony surname: Howell fullname: Howell, Anthony organization: Manchester University NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road, Division of Cancer Sciences, The University of Manchester – sequence: 8 givenname: Sacha J. surname: Howell fullname: Howell, Sacha J. email: sacha.howell@manchester.ac.uk organization: Manchester University NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road, Division of Cancer Sciences, The University of Manchester |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39695332$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuFDEQHKEgEkJ-gAOyxIXLgO32Y3xCKCIQsRIXcra8np7NrLzjwZ4h2j_gs-N9EBIOnGxVV1e12_WyOhnigFX1mtH3jELzIQvBtaopFzWljEHNn1VnXAOrDWh98uh-Wl3kvKaUAlCtJX9RnYJRRgLws-r3Ig4rMmHakC6GEO_qeSSxI3dxgwOZEroJ21JKJPuEBWpxQr_D3LQde-8CaWc_leN2O2Iag8u9I4Ue4nIOLpEB4xHsB-JIgVZIbr4d5fpi7nEoPq-q550LGS-O53l1c_X5x-XXevH9y_Xlp0XtATSvDRXGt7xdtpxrQZUwAtEIaUQLnCppgDNJnQCxdB1vlfeeSaBGd0Y3qnNwXl0fdNvo1nZM_calrY2ut3sgppV1aep9QCsMqOLJG980gilu5NIbL7BVjRBGiaL18aA1zssNtvuHuPBE9Gll6G_tKv6yjCkpG26KwrujQoo_Z8yT3fTZYwiu7G3OFpjQDLhkqlDf_kNdxzkNZVcWOJeNaISCwnrzeKSHWf78eCHwA8GnmHPC7oHCqN0lyx6SZUuy7D5ZdtcEh6ZcyMMK01_v_3TdA_PEz2M |
| Cites_doi | 10.1002/cncr.31528 10.1200/JCO.2010.28.0784 10.1245/s10434-019-07814-w 10.1016/S1470-2045(14)71171-4 10.1056/NEJMoa044383 10.1200/JCO.2015.61.4743 10.1016/j.amjsurg.2021.07.020 10.1080/13697137.2017.1342619 10.1016/j.pathol.2015.11.015 10.1016/j.breast.2021.07.020 10.6004/jnccn.2023.0046 10.1136/bmj.m1570 10.1016/j.ejso.2023.107292 10.1002/cncr.31061 10.1186/s12885-017-3082-2 10.1093/jnci/djq414 10.1200/JCO.2017.75.9480 10.1056/NEJMsr1407164 10.1001/jamaoncol.2016.3022 10.1200/JCO.2007.14.8833 10.1093/jnci/90.18.1371 10.1159/000533673 10.1158/1940-6207.CAPR-13-0222 10.1016/S0140-6736(13)62292-8 10.1016/j.crad.2018.04.004 10.1067/j.cpradiol.2018.06.004 10.1007/s10549-012-1975-y 10.1136/bmj-2023-077039 10.1001/jamasurg.2023.6382 10.1093/jnci/djt124 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). Copyright Nature Publishing Group Dec 2024 The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: Copyright Nature Publishing Group Dec 2024 – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1038/s44276-024-00113-2 |
| DatabaseName | Springer Nature OA Free Journals (Selected full-text) CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) Coronavirus Research Database ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2731-9377 |
| EndPage | 7 |
| ExternalDocumentID | oai_doaj_org_article_493637228c88416295bc9c4ed6844964 PMC11655829 39695332 10_1038_s44276_024_00113_2 |
| Genre | Journal Article |
| GeographicLocations | United Kingdom--UK |
| GeographicLocations_xml | – name: United Kingdom--UK |
| GrantInformation_xml | – fundername: National Institute for Health Research Manchester Biomedical Research Centre grantid: NIHR203308; NIHR203308; NIHR203308 – fundername: National Institute for Health Research Manchester Biomedical Research Centre grantid: NIHR203308 |
| GroupedDBID | 0R~ AAJSJ AJTQC ALMA_UNASSIGNED_HOLDINGS C6C EBLON GROUPED_DOAJ M~E NAO RPM SNYQT AASML AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA HMCUK K9. PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS UKHRP 7X8 5PM |
| ID | FETCH-LOGICAL-c3372-9049cd2dbd227406494ee94594d32065932150a434baf2d6ccc153097f9786fa3 |
| IEDL.DBID | DOA |
| ISSN | 2731-9377 |
| IngestDate | Wed Aug 27 01:32:14 EDT 2025 Thu Aug 21 18:30:28 EDT 2025 Fri Sep 05 14:28:21 EDT 2025 Sat Aug 23 12:44:21 EDT 2025 Sun Mar 30 02:12:40 EDT 2025 Tue Jul 01 03:35:42 EDT 2025 Fri Feb 21 02:36:01 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3372-9049cd2dbd227406494ee94594d32065932150a434baf2d6ccc153097f9786fa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/493637228c88416295bc9c4ed6844964 |
| PMID | 39695332 |
| PQID | 3225848463 |
| PQPubID | 7343558 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_493637228c88416295bc9c4ed6844964 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11655829 proquest_miscellaneous_3147132516 proquest_journals_3225848463 pubmed_primary_39695332 crossref_primary_10_1038_s44276_024_00113_2 springer_journals_10_1038_s44276_024_00113_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20241218 |
| PublicationDateYYYYMMDD | 2024-12-18 |
| PublicationDate_xml | – month: 12 year: 2024 text: 20241218 day: 18 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BJC reports |
| PublicationTitleAbbrev | BJC Rep |
| PublicationTitleAlternate | BJC Rep |
| PublicationYear | 2024 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | IT Rubio (113_CR11) 2024; 50 TB Bevers (113_CR13) 2023; 21 ME Sherman (113_CR29) 2024; 159 RA Vierkant (113_CR35) 2017; 17 E Falomo (113_CR32) 2019; 48 GS Mannu (113_CR33) 2020; 369 SE Pinder (113_CR3) 2018; 73 K Freeman (113_CR10) 2024; 384 113_CR4 113_CR23 113_CR24 TA King (113_CR8) 2015; 33 113_CR26 JA Glover (113_CR1) 2012; 133 K Ghosh (113_CR38) 2010; 102 AA Renshaw (113_CR7) 2016; 48 113_CR22 C Elfgen (113_CR30) 2024; 19 LC Hartmann (113_CR6) 2005; 353 AC Beck (113_CR31) 2022; 223 MG Valero (113_CR34) 2020; 27 113_CR2 JC Boughey (113_CR17) 2010; 28 J Cuzick (113_CR19) 2015; 16 TS Menes (113_CR28) 2017; 3 RD Frank (113_CR18) 2018; 124 LC Hartmann (113_CR5) 2014; 7 KC Godley (113_CR25) 2017; 20 VS Pankratz (113_CR16) 2008; 26 LC Hartmann (113_CR37) 2015; 372 JA Tice (113_CR36) 2013; 105 AC Degnim (113_CR15) 2018; 36 113_CR12 AR Donaldson (113_CR27) 2018; 124 113_CR14 J Cuzick (113_CR20) 2014; 383 MC van Maaren (113_CR9) 2021; 59 B Fisher (113_CR21) 1998; 90 |
| References_xml | – volume: 124 start-page: 3319 year: 2018 ident: 113_CR18 publication-title: Cancer doi: 10.1002/cncr.31528 – volume: 28 start-page: 3591 year: 2010 ident: 113_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.28.0784 – volume: 27 start-page: 736 year: 2020 ident: 113_CR34 publication-title: Ann Surg Oncol doi: 10.1245/s10434-019-07814-w – volume: 16 start-page: 67 year: 2015 ident: 113_CR19 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71171-4 – volume: 353 start-page: 229 year: 2005 ident: 113_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa044383 – volume: 33 start-page: 3945 year: 2015 ident: 113_CR8 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.61.4743 – ident: 113_CR23 – volume: 223 start-page: 94 year: 2022 ident: 113_CR31 publication-title: Am J Surg doi: 10.1016/j.amjsurg.2021.07.020 – volume: 20 start-page: 313 year: 2017 ident: 113_CR25 publication-title: Climacteric doi: 10.1080/13697137.2017.1342619 – volume: 48 start-page: 25 year: 2016 ident: 113_CR7 publication-title: Pathology doi: 10.1016/j.pathol.2015.11.015 – volume: 59 start-page: 376 year: 2021 ident: 113_CR9 publication-title: Breast doi: 10.1016/j.breast.2021.07.020 – ident: 113_CR4 – volume: 21 start-page: 900 year: 2023 ident: 113_CR13 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2023.0046 – ident: 113_CR2 – volume: 369 start-page: m1570 year: 2020 ident: 113_CR33 publication-title: BMJ doi: 10.1136/bmj.m1570 – volume: 50 year: 2024 ident: 113_CR11 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2023.107292 – volume: 124 start-page: 459 year: 2018 ident: 113_CR27 publication-title: Cancer doi: 10.1002/cncr.31061 – volume: 17 year: 2017 ident: 113_CR35 publication-title: BMC Cancer doi: 10.1186/s12885-017-3082-2 – volume: 102 start-page: 1716 year: 2010 ident: 113_CR38 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djq414 – volume: 36 start-page: 1840 year: 2018 ident: 113_CR15 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.75.9480 – volume: 372 start-page: 78 year: 2015 ident: 113_CR37 publication-title: N Engl J Med doi: 10.1056/NEJMsr1407164 – volume: 3 start-page: 36 year: 2017 ident: 113_CR28 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.3022 – volume: 26 start-page: 5374 year: 2008 ident: 113_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.8833 – volume: 90 start-page: 1371 year: 1998 ident: 113_CR21 publication-title: JNCI J Natl Cancer Inst doi: 10.1093/jnci/90.18.1371 – ident: 113_CR14 – ident: 113_CR22 – volume: 19 start-page: 62 year: 2024 ident: 113_CR30 publication-title: Breast Care doi: 10.1159/000533673 – volume: 7 start-page: 211 year: 2014 ident: 113_CR5 publication-title: Cancer Prev Res doi: 10.1158/1940-6207.CAPR-13-0222 – volume: 383 start-page: 1041 year: 2014 ident: 113_CR20 publication-title: Lancet doi: 10.1016/S0140-6736(13)62292-8 – ident: 113_CR24 – volume: 73 start-page: 682 year: 2018 ident: 113_CR3 publication-title: Clin Radiol doi: 10.1016/j.crad.2018.04.004 – volume: 48 start-page: 462 year: 2019 ident: 113_CR32 publication-title: Curr Probl Diagn Radiol doi: 10.1067/j.cpradiol.2018.06.004 – volume: 133 start-page: 779 year: 2012 ident: 113_CR1 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-012-1975-y – volume: 384 start-page: e077039 year: 2024 ident: 113_CR10 publication-title: BMJ doi: 10.1136/bmj-2023-077039 – ident: 113_CR26 – ident: 113_CR12 – volume: 159 start-page: 193 year: 2024 ident: 113_CR29 publication-title: JAMA Surg doi: 10.1001/jamasurg.2023.6382 – volume: 105 start-page: 1043 year: 2013 ident: 113_CR36 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djt124 |
| SSID | ssj0003307752 |
| Score | 2.2811332 |
| Snippet | Background
Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk... Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction... BackgroundAtypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk... Abstract Background Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 90 |
| SubjectTerms | Age Annual reports Biomedical and Life Sciences Biomedicine Biopsy Breast cancer Cancer Research Ethnicity Family medical history Histopathology Hyperplasia Mammography Medical screening Oncology Patients Prevention Risk factors Surveillance Womens health |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LixQxEA66gngR39u6SgRvGrY7SXeSk6i4LL5ODswt5NW7C0t3Ow_Ef-DPtiqTmWV8nQaSMCSpStVXqa8rhLzgUkReK8WcbxKT4CMY4GbOPPe8NwYwe8xsiy_d6Ux-mLfzcuG2LLTKrU3MhjqOAe_Ij1HxtARvKV5P3xi-GoXZ1fKExnVyowEkgk83qLna3bFArK5Uy8u3MrXQx0spuULWrWQIhgTje_4ol-3_G9b8kzL5W940u6OTO-R2wZH0zUbwd8m1NNwjNz-XTPl98vPTOJxRtLu0B1GP39l6omNPc8UFmunlKULXgoLdgFiWxoTpBGhzqx8TSo5iJVj4OYdIdTHlry0pDL8cPTJX6YDU89x4MVBHL5FRTmcfy9_BnGleRHpAZifvv747ZeXVBRaEUJwZiBlC5NFHDhErIBYjUzKyNTIKjllYASihdlJI73oeuxACWM3aqB4C0q534iE5GMYhHRIaokyh1dHFupd9Cq7uahienGlc672qyMvt3ttpU1zD5qS40HYjKQuSyrQ7YXlF3qJ4diOxMHZuGBdntpwzK43oYBVcB40JVW5aH0yQKXZaStPJihxthWvLaV3aK92qyPNdN5wzTJ442M81jGnAjQtAg11FHm10YTcTYTpk6cIM9Z6W7E11v2e4OM-1vLH6Uau5qcirrUJdzevfe_H4_8t4Qm5x1PGGs0YfkYPVYp2eAnha-Wf5hPwCXVEXPA priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals (Selected full-text) dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBYhhdJLadOX2ySo0Fsrao9kWTq2S0Po69SF3IxeTgLBXja7hP6D_uzOaO0N26aHnhak2WWsGY2-8XyaZewNKBmhbBrhfJWEwjNCIG4G4cFDZy1i9pjZFt_16Vx9PqvP9hhMd2EyaT-3tMxhemKHvb9WChqiyypBKEYKDLv3TCNr8uqZnm3fq2B-3jQ1jPdjSmnu-OrOGZRb9d-FL_-mSf5RK81H0Mkj9nDEjvzDRtvHbC_1B-z-t7E6_oT9-jr055xiLe_QvMONWC_40PHcZYFnSnmKOLXkGCswf-UxUQkBx9zq54Ksxan7K35cYHa6XOQblhzFrwZPbFXeE908D1723PErYpHz-Zfx51Bnnh8iPWXzk08_Zqdi_KcFEaRsQFjME0KE6CNgloooxaqUrKqtihKo8ioRGZROSeVdB1GHEDBSlrbpMAnVnZPP2H4_9OkF4yGqFGoTXSw71aXgSl2ieHK2crX3TcHeTmvfLjYNNdpcCJem3ViqRUtlqp1soWAfyTxbSWqGnQeG5Xk7OkerrNT4FGCCoSIq2NoHG1SK2ihltSrY4WTcdtyh1y0FMqMQfcmCvd5O496igonD9VyjTIVHt0QEqAv2fOMLW02k1cTMRQ3NjpfsqLo7019e5P7d1PGoNmAL9m5yqFu9_r0WL_9P_BV7AOTzFYjKHLL91XKdjhBArfxx3jG_AZitFOg priority: 102 providerName: Springer Nature |
| Title | Long term follow-up of women treated for screen detected atypical ductal hyperplasia or lobular neoplasia in a large UK screening centre |
| URI | https://link.springer.com/article/10.1038/s44276-024-00113-2 https://www.ncbi.nlm.nih.gov/pubmed/39695332 https://www.proquest.com/docview/3225848463 https://www.proquest.com/docview/3147132516 https://pubmed.ncbi.nlm.nih.gov/PMC11655829 https://doaj.org/article/493637228c88416295bc9c4ed6844964 |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagSIgL4k1KWRmJG1hNbMeP43bVqlqgQsBKe4sc26GVqmS13RXqP-BnM-Nkly4PceEUybaiycx4_E3my4SQ11yKwHOtmauLyCScEQxwM2c1r3ljLWD2kNgWZ-p0Jqfzcn7jV1_ICevbA_eKO5RWKKE5N95ghYzbsvbWyxiUkdKq1Ak0t_mNZApjMGTpWpd8-EomF-bwSkqukW8rGcIgwfjOSZQa9v8JZf5OlvylYpoOopMH5P6AIOm4l_whuRXbR-Tuh6FG_ph8f9-1XylGXNqAkbtvbL2gXUNTrwWaiOUxwNSSQsSALJaGiIUEGHOr6wXajGIPWLicQ466XKTvLCksv-xq5KzSFknnafCipY5eIpeczt4NtwOZaXqI-ITMTo6_TE7Z8L8F5gWomFnIFnzgoQ4cclXAKlbGaGVpZRAc668C8EHupJC1a3hQ3nuIl7nVDaSiqnHiKdlruzY-J9QHGX1pggt5I5voXa5yWB6dLVxZ1zojbza6rxZ9W40qlcOFqXpLVWCpRLgTFc_IEZpnuxJbYqcBcJRqcJTqX46SkYONcathn15VGM6MBAwmMvJqOw07DMsmDvS5hjUFHOACcKDKyLPeF7aSCKuQnwsSmh0v2RF1d6a9OE9dvLHvUWm4zcjbjUP9lOvvutj_H7p4Qe5x3AkFZ4U5IHur5Tq-BHC1qkfktp7rEbkzHk8_T-F6dHz28ROMTtRklPbYKL0R-wF9GCPM |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcEG8CBYwEJ7CatZ1sfKgQhVZbdrtCqCv1FhzbaStVybIPVf0H_Cp-GzPeZKvldespkm1FY894Zuz5PAPwWijpRNzrcVN0PVdoIzj6zYIXohCl1uizu4C2GKX9sfp8nBxvwM_2LQzBKludGBS1qy3dkW-T4GUKraV8P_nOqWoURVfbEhqmKa3gdkKKseZhx8BfXuARbrZz8An5_UaI_b2jj33eVBngVsqe4Bp9ZOuEK5zAExpaaK281yrRyklBUUeJVjE2SqrClMKl1lrUErHulXgAS0sj8b83YFPRBUoHNnf3Rl--rm55pKQUc6J5rRPLbHumlOgR7ldxcsckF2sWMRQO-Ju3-ydo87fIbTCI-3fhTuPJsg9L0bsHG766DzcPm1j9A_gxrKsTRpqflShs9QVfTFhdspDzgQWAu3fYNWWoufA0zZyngAa2mfnlhGSHUS5a_JziWXk6Ce89GQ4_rwvCzrKKwO-h8axihp0Tpp2NB83vkGYWJuEfwvhaOPIIOlVd-SfArFPeJpkzLi5V6a2J0xiHe6O7JimKXgRv27XPJ8v0HnkIy8ssX3IqR04F4J_MRQS7xJ7VSErNHRrq6Une7PRcaZniLERmMwrpCp0UVlvlXZoppVMVwVbL3LzRF7P8SrojeLXqxp1O4RuD67nAMV10JCT6o2kEj5eysKJE6pRwwkhhtiYla6Su91RnpyGbOOVfSjKhI3jXCtQVXf9ei6f_n8ZLuNU_Ohzmw4PR4BncFiTvXcG72RZ05tOFf46u3Lx40ewXBt-ue4v-An6mWC4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LbxMxEB6VIlVcEG8WChiJG1js2l6vfYRAVGipOBCpN8uvbStVu1GaCPUf9GczdnaDAuXAKZI9iWY94_E3O58nAG-Y4IGVTUOtqyIVeEZQxM2MOuZYqzVi9pDZFsfyYCa-ntQnOyDHuzCZtJ9bWuYwPbLD3l8KwZpElxU0oRhOMR8M7S24rfBITEnXRE4271YwR2-amg13ZEqubvj61jmU2_XfhDH_pkr-US_Nx9D0Htwd8CP5sNb4PuzE7gHsfRsq5A_h-qjvTkmKt6RFE_c_6WpO-pbkTgsk08pjwKkFwXiBOSwJMZURcMwur-bJYiR1gMWPM8xQF_N8y5Kg-EXvEmOVdIlyngfPO2LJRWKSk9nh8HOoM8kPER_BbPr5x-SADv-2QD3nDaMacwUfWHCBYaaKSEWLGLWotQicpeorR3RQWsGFsy0L0nuP0bLUTYuJqGwtfwy7Xd_Fp0B8ENHXKthQtqKN3payRPFodWVr55oC3o5rb-brphomF8O5MmtLGbRUpttxwwr4mMyzkUwNsfNAvzg1g4MYobnEp2DKq1RIZbp2XnsRg1RCaCkK2B-Na4ZdemlSMFMCERgv4PVmGvdXKppYXM8VylR4fHNEgbKAJ2tf2GjCtUzsXNRQbXnJlqrbM935We7hnboe1YrpAt6NDvVbr3-vxbP_E38Fe98_Tc3Rl-PD53CHJfevGK3UPuwuF6v4AvHU0r3Mm-cXs2QY4A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long+term+follow-up+of+women+treated+for+screen+detected+atypical+ductal+hyperplasia+or+lobular+neoplasia+in+a+large+UK+screening+centre&rft.jtitle=BJC+reports&rft.au=Brown%2C+Nicole+L&rft.au=Pritchard%2C+Susan&rft.au=Harkness%2C+Elaine+F&rft.au=Lim%2C+Yit&rft.date=2024-12-18&rft.issn=2731-9377&rft.eissn=2731-9377&rft.volume=2&rft.issue=1&rft.spage=90&rft_id=info:doi/10.1038%2Fs44276-024-00113-2&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2731-9377&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2731-9377&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2731-9377&client=summon |